Skip to main
KNSA
KNSA logo

KNSA Stock Forecast & Price Target

KNSA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kiniksa Pharmaceuticals has demonstrated a robust financial trajectory, achieving 2024 Arcalyst revenue of $417 million, which reflects a remarkable 79% year-over-year increase and surpasses initial management guidance. This significant revenue growth has been attributed to an expanding prescriber base, which rose to over 2,850 unique prescribers by 4Q24, marking a steady increase from prior quarters. Additionally, the average duration of Arcalyst therapy in recurrent pericarditis has also improved, rising to approximately 27 months in 4Q24 from 23 months in 1Q24, signaling enhanced treatment effectiveness and patient retention.

Bears say

Kiniksa Pharmaceuticals faces significant challenges due to potential competition from superior products, which could negatively impact its market position and pricing power. Additionally, the adoption of their product Arcalyst for recurrent pericarditis may fall short of expectations, further jeopardizing revenue potential. These factors, combined with regulatory and commercial risks associated with pricing in the rare disease segment, contribute to a negative outlook for the company's stock.

KNSA has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kiniksa Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kiniksa Pharmaceuticals Ltd (KNSA) Forecast

Analysts have given KNSA a Buy based on their latest research and market trends.

According to 7 analysts, KNSA has a Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kiniksa Pharmaceuticals Ltd (KNSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.